Loss of Tid1/DNAJA3 Co-Chaperone Promotes Progression and Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Novel Model to Stratify Risk of Recurrence

por Chen, Kuan-Yang, Huang, Yi-Hsiang, Teo, Wan-Huai, Chang, Ching-Wen, Chen, Yu-Syuan, Yeh, Yi-Chen, Lee, Chieh-Ju, Lo, Jeng-Fan
Publicado 2021

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

por Wu, Chi-Jung, Lee, Pei-Chang, Hung, Ya-Wen, Lee, Chieh-Ju, Chi, Chen-Ta, Lee, I-Cheng, Hou, Ming-Chih, Huang, Yi-Hsiang
Publicado 2022

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma

por Lee, Pei-Chang, Chao, Yee, Chen, Ming-Huang, Lan, Keng-Hsin, Lee, Chieh-Ju, Lee, I-Cheng, Chen, San-Chi, Hou, Ming-Chih, Huang, Yi-Hsiang
Publicado 2020

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma

por Lee, Pei-Chang, Wu, Chi-Jung, Hung, Ya-Wen, Lee, Chieh Ju, Chi, Chen-Ta, Lee, I-Cheng, Yu-Lun, Kuo, Chou, Shih-Hsuan, Luo, Jiing-Chyuan, Hou, Ming-Chih, Huang, Yi-Hsiang
Publicado 2022

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

por Pinato, David J., Kaneko, Takahiro, Saeed, Anwaar, Pressiani, Tiziana, Kaseb, Ahmed, Wang, Yinghong, Szafron, David, Jun, Tomi, Dharmapuri, Sirish, Naqash, Abdul Rafeh, Muzaffar, Mahvish, Navaid, Musharraf, Lee, Chieh-Ju, Bulumulle, Anushi, Yu, Bo, Paul, Sonal, Nimkar, Neil, Bettinger, Dominik, Hildebrand, Hannah, Abugabal, Yehia I., Ang, Celina, Marron, Thomas U., Khan, Uqba, Personeni, Nicola, Rimassa, Lorenza, Huang, Yi-Hsiang
Publicado 2020

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

por Fessas, Petros, Kaseb, Ahmed, Wang, Yinghong, Saeed, Anwaar, Szafron, David, Jun, Tomi, Dharmapuri, Sirish, Rafeh Naqash, Abdul, Muzaffar, Mahvish, Navaid, Musharraf, Khan, Uqba, Lee, ChiehJu, Bulumulle, Anushi, Yu, Bo, Paul, Sonal, Nimkar, Neil, Bettinger, Dominik, Benevento, Francesca, Hildebrand, Hannah, Pressiani, Tiziana, Abugabal, Yehia I, Personeni, Nicola, Huang, Yi-Hsiang, Rimassa, Lorenza, Ang, Celina, Marron, Thomas, Pinato, David J
Publicado 2020

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma

por Jun, Tomi, Ozbek, Umut, Dharmapuri, Sirish, Hardy-Abeloos, Camille, Zhu, Huili, Lin, Jung-Yi, Personeni, Nicola, Pressiani, Tiziana, Nishida, Naoshi, Lee, Pei-Chang, Lee, Chieh-Ju, Hildebrand, Hannah, Nimkar, Neil, Paul, Sonal, Fessas, Petros, Naeem, Muntaha, Bettinger, Dominik, Khan, Uqba, Saeed, Anwaar, Huang, Yi-Hsiang, Kudo, Masatoshi, Rimassa, Lorenza, Marron, Thomas U., Pinato, David J., Ang, Celina
Publicado 2021

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

por Pinato, David J, Kaseb, Ahmed, Wang, Yinghong, Saeed, Anwaar, Szafron, David, Jun, Tomi, Dharmapuri, Sirish, Naqash, Abdul Rafeh, Muzaffar, Mahvish, Navaid, Musharraf, Khan, Uqba, Lee, ChiehJu, Bulumulle, Anushi, Yu, Bo, Paul, Sonal, Fessas, Petros, Nimkar, Neil, Bettinger, Dominik, Hildebrand, Hannah, Pressiani, Tiziana, Abugabal, Yehia I, Personeni, Nicola, Huang, Yi-Hsiang, Lozano-Kuehne, Jingky, Rimassa, Lorenza, Ang, Celina, Marron, Thomas U
Publicado 2020

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

por Sharma, Rohini, Pillai, Anjana, Marron, Thomas Urban, Fessas, Petros, Saeed, Anwaar, Jun, Tomi, Dharmapuri, Sirish, Szafron, David, Naqash, Abdul Rafeh, Gampa, Anuhya, Wang, Yinghong, Khan, Uqba, Muzaffar, Mahvish, Lee, Chieh‐Ju, Lee, Pei‐Chang, Bulumulle, Anushi, Paul, Sonal, Bettinger, Dominic, Hildebrand, Hannah, Yehia, Mohammed, Pressiani, Tiziana, Kaseb, Ahmed, Huang, Yi‐Hsiang, Ang, Celina, Kudo, Masatoshi, Nishida, Naoshi, Personeni, Nicola, Rimassa, Lorenza, Pinato, David James
Publicado 2022